Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.9 million.

  • Enanta Pharmaceuticals' Net Income towards Common Stockholders rose 4644.24% to -$11.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$71.4 million, marking a year-over-year increase of 3180.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 2941.25% up from last year.
  • Enanta Pharmaceuticals' Net Income towards Common Stockholders amounted to -$11.9 million in Q4 2025, which was up 4644.24% from -$18.6 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at -$11.9 million for Q4 2025, and its period low was -$39.1 million during Q2 2023.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$28.4 million (2023), whereas its average is -$27.5 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 50391.34% in 2021, then soared by 4644.24% in 2025.
  • Enanta Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then soared by 46.44% to -$11.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$11.9 million for Q4 2025, versus -$18.6 million for Q3 2025 and -$18.3 million for Q2 2025.